Matt Field presents new evidence on the risks and benefits of nalmefene in the treatment of adult alcohol dependence, which casts further doubt over the controversial recommendations made by NICE and the European Medicines Agency.
[read the full story...]
Samuele Cortese publishes his debut Mental Elf blog on a meta-analysis of n-of-1 trials, which shows that amphetamine derivatives and methylphenidate are superior to placebo, in the short term, for paediatric ADHD.
[read the full story...]
Joanne Wallace considers a recent health technology assessment on the risks and benefits of psychotropic medication in pregnancy, which supports previous associations between valproate and adverse child outcomes.
[read the full story...]
Join us at 2-3pm on Wednesday 18th May for the #UCLJournalClub, which will be live broadcasted on YouTube and live tweeted by the @LearningDisElf
[read the full story...]
John Baker presents a systematic review of preferences for medication-associated outcomes in mental disorders, which concludes that we just don’t know what value mental health service users place on the different outcomes that come from taking psychiatric medication.
[read the full story...]
John Baker summarises a review of commonly prescribed medication that covers seven psychiatric drugs, including antidepressants, antipsychotics, benzodiazepines, amphetamines, methylphenidate and cholinesterase inhibitors.
[read the full story...]
Eleanor Kennedy summarises a recent Cochrane review of pharmacotherapy for chronic cognitive impairment in traumatic brain injury, which finds insufficient evidence to support its use.
[read the full story...]
Caroline Struthers reports on the findings of a follow-up paper of the DOMINO-AD trial, which compares Donepezil and Memantine for Moderate to Severe Alzheimer’s Disease, and looks at the effects these two drugs have on nursing home placement.
[read the full story...]
John Baker summarises a recent Cochrane systematic review of psychosocial interventions for benzodiazepine harmful use, abuse or dependence.
[read the full story...]
Rosalyn Nelson presents the latest Cochrane systematic review of Rivastigmine for Alzheimer’s disease, which brings together the results of 7 industry sponsored or funded trials, and concludes that Rivastigmine may be of benefit to people with Alzheimer’s disease.
[read the full story...]
